



# MARYLAND SOCIETY OF HEALTH-SYSTEM PHARMACY

## ALL DAY CE SEMINAR – FALL SESSION SATURDAY NOVEMBER 12, 2011 THE CONFERENCE CENTER AT THE MARITIME INSTITUTE

### AGENDA & PROGRAM OBJECTIVES

I. 7:15 – 8:25 am      **Registration & Please Join our for Continental Breakfast**

II. 7:00 – 8:00 am      **Maryland Directors of Pharmacy & Leadership Group**

III. 8:30 – 9:30 am      **Optimizing Bone Health in Cancer Patients**

Jane M. Pruemmer, PharmD, BCOP, FASHP, Professor,  
James Winle College of Pharmacy, University of Cincinnati

#### **LEARNING OBJECTIVES**

1. Describe the prevalence, morbidity, mortality, and impact on quality of life of skeletal-related events in patients with cancer.
2. Explain normal bone remodeling and the pathogenesis of skeletal-related events in patients with cancer.
3. Discuss the mechanism of action, efficacy, and safety of agents used for treating bone metastases and slowing or preventing cancer treatment-induced bone loss (CTIBL).
4. Recommend a pharmacologic regimen for a patient with bone metastases or CTIBL.
5. Identify new or emerging bone-targeted therapies for patients with bone metastases and describe mechanisms of action and potential roles in improving bone health in cancer patients.

**OR**                      *Pharmacy Technician Track –*

#### **Too Many to Count: Herbal Drug Interactions with Warfarin**

Kathryn Kissler, PharmD, Assistant Professor  
University of Maryland, School of Pharmacy

#### **LEARNING OBJECTIVES**

1. Access two drug information resources which have the ability to check herbal drug interactions
2. Identify potential drug interactions between warfarin and an herbal product
3. Apply drug information obtained about a potential drug interaction between warfarin and an herbal product to a patient case

IV. 9:30 - 10:30 am      **The Pharmacist's Role in the Prevention & Treatment of Breast Cancer**

James Trovato, PharmD, MBA, BCOP, Associate Professor  
University of Maryland, School of Pharmacy

#### **LEARNING OBJECTIVES**

1. Describe screening and risk reduction strategies for breast cancer.
2. Outline the pharmacological treatments for metastatic breast cancer with respect to their mechanisms of action, efficacy, and toxicities.
3. Recognize common adverse effects associated with the treatment of metastatic breast cancer.
4. Devise and communicate a plan to manage adverse effects associated with the treatment of metastatic breast cancer.

**OR**                      *Pharmacy Technician Track – A302*

#### **Cervical Cancer...an Ounce of Prevention**

Katharine McGrath Kinsman, PharmD, Clinical Specialist,  
The Johns Hopkins Hospital

**LEARNING OBJECTIVES**

1. Identify the virus associated with cervical cancer
2. Define which patient populations should receive vaccination
3. Summarize the current screening recommendations to prevent cervical cancer
4. Outline the treatment for early, advanced, and recurrent cervical cancer

V. 10:30 - 11:00 am **Break with Corporate Sponsors**

VI. 11:00 - 12:15 pm **Joint Pharmacist & Technician Track - Auditorium**

**Health Care Reform Update**

David Chen, RPh, MBA, Director of Pharmacy Practice Sections

**LEARNING OBJECTIVES**

1. Discuss provisions of healthcare reform on expanding insurance coverage
2. Describe changes to Part D coverage
3. Describe changes to quality initiatives

VII. 12:15 – 1:30 pm **Lunch & Fall Awards Presentations –**

VIII. 1:30 – 2:30 pm **New Antibiotics: In Short Supply and Fewer to Come**

Edina Avdic, PharmD, MBA, BCPS, AQ-ID, Clinical Specialist

The Johns Hopkins Hospital

**LEARNING OBJECTIVES**

1. Summarize the available data on fidaxomicin, ceftaroline, telavancin, and doripenem
2. State one advantage and one disadvantage of the following: fidaxomicin, ceftaroline, telavancin, and doripenem
3. Identify the role of fidaxomicin, ceftaroline, telavancin, and doripenem in current clinical practice

IX. 2:30 – 3:30 pm **Keep Young and Beautiful: HIV and Women in 2011**

Beulah P. Sabundayo, PharmD, MPH, Research Associate,

The Johns Hopkins Bloomberg School of Public Health

**LEARNING OBJECTIVES (pharmacists)**

1. Discuss prevalence of HIV among US women.
2. Identify barriers to HIV infected women's use of health services
3. List acceptable contraceptive methods in HIV infected women.
4. Determine appropriate adherence measures for HIV infected women

**LEARNING OBJECTIVES (technicians)**

1. Identify need for additional counseling for HIV infected women
2. Determine when HIV infected women should be referred to a pharmacist for additional medical information.

X. 3:30 – 4:30 pm **Drug Dependency & Recovery: A First Hand Account**

**LEARNING OBJECTIVES**

1. Explain the prevalence and risk of addiction for health care professionals.
2. Describe PEAC's role in establishing a path to recovery for the addicted pharmacist or technician while maintaining or re-obtaining the ability to continue working in the field of pharmacy practice.
3. Briefly summarize the addicted pharmacist/technician's impairment and to recognize impairment in yourself or your co-workers.
4. List preferred ways of helping the impaired individual.

XI. 4:20 – 4:30 pm

**Wrap Up – and Adjournment**